AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KNSA

Ragosa Mark sold $3.4M of KNSA

Ragosa Mark (CHIEF FINANCIAL OFFICER) sold 36,783 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $92.16 ($91.40–$94.01, $3.39M total) across 4 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ragosa Mark
Published Nov 3, 2026, 11:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KNSA
Bearish
medium confidence
Mentioned
$KNSA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KNSABearishLow
01

Why it matters

The transaction is a primary disclosure but modest in size, likely causing only slight price movement.

02

Market read

Provides fresh insider transaction data for KNSA, useful for short‑term traders monitoring insider activity.

03

What to watch

The CFO may be diversifying holdings; the sale does not reflect company fundamentals.

Relevance 5/10Novelty 3/10Timing: post‑market today

Background

Form 4 filings disclose insider transactions; a CFO sale is noteworthy for shareholders.

Company-level read

Ticker impact

$KNSABearishMedium confidence
Context

CFO Ragosa Mark sold $3.4M of KNSA shares via a 10b5‑1 plan on 2026‑11‑02.

Expected impact

likely slight downward pressure as the market prices the CFO's sale.

Evidence & confidence

A $3.4M sale by the CFO is a material insider transaction but not large enough to trigger a major move.

Market effects

Sector

Minimal impact on the biotech/pharma sector; insider sales are routine.

Regional

No significant regional effect.

Global

Limited to investors tracking KNSA.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move and not a negative signal.

Key entities

  • company
    Kiniksa Pharmaceuticals International, plc

    Biopharmaceutical company listed on Nasdaq under ticker KNSA.

  • person
    Ragosa Mark

    Chief Financial Officer of KNSA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KNSA insider trading history →

Related articles

$KNSAMedAI 8/10

Kiniksa Pharmaceuticals, Ltd. Q3 2026 Earnings Call Summary

Kiniksa Pharmaceuticals reported Q3 2026 revenue growth of 58% YoY, driven by increased market penetration and physician adoption of IL-1 inhibition. The company raised full-year revenue guidance to $1.045B-$1.050B. It plans to initiate a Phase I trial for KPL-1161 by year-end and expects KPL-387 Phase III data in H2 2027. Kiniksa ended the quarter with $568.8M in cash.

finance.yahoo.com
$KNSAHigh

Kiniksa (KNSA) Q3 2026 Earnings Call Transcript

Kiniksa reported Q3 2026 revenue of $286M for ARCALYST, up 58% YoY. The company expects KPL-387 trial data in 2H 2027 and aims for a 2028-2029 launch. ARCALYST penetration in recurrent pericarditis patients reached 23%. Kiniksa forecasts $1B+ in 2026 ARCALYST revenue and is investing in AI-driven patient identification and marketing campaigns. Operating income was $54.2M, net income $47.3M, with $568.8M in cash at quarter-end.

finance.yahoo.com